Considering the role of FOXM1 in proliferation and AFP expression in AFP-positive HCC cells, it is possible that the inhibition of FOXM1 with a very low concentration of carfilzomib might be therapeutically effective to suppress the proliferation of AFP-positive liver cancer stem cells. Here, FOXM1 is linked to hepatocellular carcinoma.